Teva Pharma

Valuation Analysis

About the Company

Teva Pharma en bref

Teva Pharma (TEVA) is currently trading at 27,45 € with a market capitalization of 32,0 Md €. The trailing P/E ratio stands at 23.48x, with a forward P/E of 10.16x. The 52-week range spans from 13,08 € to 32,59 €; the current price is 15.8% below the yearly high. Year-over-year revenue growth stands at +2.3%. The net profit margin stands at 9.02%.

💰 Dividende

Teva Pharma currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.

📊 Avis des analystes

10 analystes évaluent Teva Pharma (TEVA) au consensus : Achat Fort. L'objectif de cours moyen est de 35,69 €, soit un potentiel de +29.99% par rapport au cours actuel. La fourchette des objectifs de cours des analystes va de 28,80 € à 43,63 €.

Teva Pharma : la thèse d'investissement en détail

Teva Pharma (TEVA) operates in the Healthcare — specifically Drug Manufacturers - Specialty & Generic — and is headquartered in Israel. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

Le scénario haussier

Earnings growth of 72.2% is outpacing revenue, a sign of operational leverage — fixed costs are being absorbed across a larger base. The combination of a 52.06% gross margin and 19.16% operating margin shows the business converts revenue into profit efficiently — a hallmark of competitive moat. Wall Street consensus sits at Strong Buy with an average price target implying roughly 29.99% upside from current levels — analyst sentiment is firmly constructive.

Le scénario baissier

Revenue growth has slowed to just 2.3%, which is below nominal GDP — the business is no longer outgrowing the broader economy. The debt-to-equity ratio of 205.6% is elevated, meaning the company relies heavily on creditors — refinancing terms will become more important than operational performance in the next economic downturn.

Valorisation en contexte

With a PEG ratio of 0.81, the price-to-earnings multiple is actually below the company's growth rate — classic value-meets-growth territory that Peter Lynch would have called a 'GARP' opportunity.

Signal Smart Money

On the institutional side, Teva Pharma appears in the disclosed holdings of Druckenmiller. Smart-money managers track positioning, fundamentals and competitive dynamics with research budgets few retail investors can match — when several converge on the same name, it is rarely random. That doesn't mean blind copying makes sense, but it does raise the bar for the bear case.

À surveiller

• The forward P/E of 10.16x is meaningfully below the trailing 23.48x — analysts expect earnings to step up; the next earnings release is the test.
• The analyst consensus price target implies 29.99% upside — if the next two quarters confirm the underlying thesis, target hikes typically follow.

Thèse d'investissement : forces et faiblesses

Aperçu technique

Price shows short-term weakness (below 50d MA) but is still in a longer-term uptrend (above 200d MA).

Profil de risque

The data points to relatively defensive market behavior, higher leverage relative to equity.

Trading Data

Related Stocks in the Same Sector

Where can I buy Teva Pharma?

Compare top-rated brokers — low fees, trusted providers, fully regulated.